Intra-Cellular Therapies, Inc.
ITCI
Ранг среди акций
#1689
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on... Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on creating innovative treatments for conditions affecting the brain and nervous system. The company achieves this by targeting the intricate cellular communication pathways within the central nervous system, primarily operating in the United States. Its commercialized product is CAPLYTA, an approved therapy for schizophrenia in adult patients. Furthermore, the company maintains a robust development pipeline, including lumateperone, which is undergoing late-stage (Phase III) clinical trials for bipolar depression and is also being investigated for autism spectrum disorder and various sleep disturbances associated with neuropsychiatric and neurological illnesses. Other key drug candidates in its pipeline include Lenrispodun (ITI-214), aimed at treating Parkinson's disease and heart failure; ITI-1284-ODT-SL, designed to address neuropsychiatric disorders and behavioral challenges in dementia; and ITI-333, intended for substance use disorders, pain management, and co-occurring psychiatric conditions like depression and anxiety. Established in 2002, Intra-Cellular Therapies, Inc. has its headquarters situated in New York, New York.
Цена акции
$131.87
Последняя синхронизация: 2025-04-02
Рыночная капитализация
$12.68B
Изменение (1 день)
0.00%
Изменение (1 год)
0.00%
Страна
US
Торговля Intra-Cellular Therapies, Inc. (ITCI)
Категория
Healthcare
Выручка компании Intra-Cellular Therapies, Inc. (ITCI)
Выручка на Dec 2024 TTM: $680.64M
Согласно последним финансовым отчетам Intra-Cellular Therapies, Inc., текущая выручка компании (TTM) составляет $680.64M. В 2023 году компания получила выручку $464.37M больше, чем выручке в 2022 году, которая составила $249.13M. Выручка — это общий доход, который компания получает от продажи товаров или услуг. В отличие от прибыли, расходы не вычитаются.
История выручки Intra-Cellular Therapies, Inc. с 2013 по 2026
Выручка на конец каждого года
| Год | Выручка | Изменить |
|---|---|---|
| 2026 (TTM) | $680.64M | -0.03% |
| 2024 | $680.85M | 46.62% |
| 2023 | $464.37M | 86.40% |
| 2022 | $249.13M | 204.91% |
| 2021 | $81.71M | 262.65% |
| 2020 | $22.53M | 37,071.49% |
| 2019 | $60.61K | 0.00% |
| 2018 | 0.00 | -100.00% |
| 2017 | $245.84K | -25.66% |
| 2016 | $330.70K | 261.96% |
| 2015 | $91.36K | -84.17% |
| 2014 | $577.30K | -78.91% |
| 2013 | $2.74M | 0.00% |
Выручка аналогичных компаний или конкурентов
| Компания | Выручка | Разница в выручке | Страна |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $6.61B | 871.39% |
IN
|
